The distinctive feature of PepGNP-Dengue lies in its design–a synthetic peptide nanoparticle-based vaccine–which aims to specifically elicit, or boost, a CD8+ T cell response, in order to provide protection without the need of vaccine-induced antibodies. Here, CD8A is linked to dengue disease.